Peer-reviewedCC BY-NCActa Dermato-Venereologica
Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study
16 affiliations
- 1Dermatological Department, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Dermatological Research Hospital, Rome, Italy
- 2Section of Dermatology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
- 3Bioinformatics Unit, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Dermatological Research Hospital, Rome, Italy
- 4Dermatologic Clinic, Sapienza University of Rome, Rome, Italy
- 5Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, Istituto Nazionale di Ricovero e Cura degli Anziani (INRCA)-IRCCS Hospital, Ancona, Italy.x
- 6Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 7Department of Dermatology, University of Pisa, Pisa, Italy; Health Science Interdisciplinary Center, Sant'Anna School of Advanced Studies, Pisa, Italy
- 8Dermatology Unit, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
- 9Dermatology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy
- 10Clinic of Dermatology, Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti, Italy
- 11Dermatology Unit, AOU of Cagliari, Department Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
- 12Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
- 13Dermatology Unit, Istituto Nazionale di Riposo e Cura per Anziani, Istituto Nazionale di Ricovero e Cura degli Anziani (INRCA)-IRCCS Hospital, Ancona, Italy.
- 14U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 15Health Science Interdisciplinary Center, Sant'Anna School of Advanced Studies, Pisa, Italy
- 16Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy; Dermatology Unit, Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy
Abstract
Atopic dermatitisis a chronic skin disease that requires long-term monitoring, which can be assessed using Atopic Dermatitis Control Tool (ADCT). Achieving minimal disease activity is also becoming an important issue in the treatment of atopic dermatitis. We aimed to identify which minimal disease sctivity patient-reported outcomes most closely reflect ADCT-defined disease control. We conducted a multicentric, observational retrospective study in patients with moderate-to-severe atopic dermatitis treated with upadacitinib. Outcome measures were collected at different time points (Week 0, 4, 16, 32, 52). Longitudinal changes were assessed with the paired Wilcoxon signedrank test; cross-sectional ADCT–patient-reported outcomes associations were evaluated at each visit using Spearman rank correlation coefficient (ρ). A total of 212 were included. All outcomes improved significantly from Week 4 onwards (all p<0.001). An ADCT score<7 was reached by 84.6% of evaluable patients at Week 4 and 90.1% at Week 52. At each timepoint, ADCT showed the strongest correlation with POEM (ρ range: 0.64–0.64) compared to other minimal disease sctivity patient-reported outcomes. These findings indicate that, among the minimal disease sctivity patient-reported outcomes, POEM most closely reflects the patient’s perception of atopic dermatitis control assessed by ADCT. Larger prospective studies are warranted to confirm these preliminary observations.
Related
- Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study
- Subcorneal Pustular Dermatosis as a Complication of Upadacitinib Therapy in a Patient with Atopic Dermatitis: A Case Report
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- Clinical Response to Upadacitinib in Treatment-Experienced Patients With Atopic Dermatitis: A Case Series From Latin America.
- Upadacitinib in refractory acquired reactive perforating collagenosis with atopic dermatitis and chronic kidney disease: a case report.
BibTeX
@article{russo2026explorative,
title = {{Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study}},
author = {Filomena Russo and Natale Schettini and Giovanni Scaglione and Ester Del Duca and Tommaso Bianchelli and Niccolò Gori and Flavia Margiotta and Laura Calabrese and Elettra Antonelli and Federica Giuliani and Viviana Piras and Sabatino Pallotta and Chiara Bocchi and Edoardo Mortato and Camilla Chello and Helena Gioacchini and Maria Cannizzaro and Marco Romanelli and Laura Lazzeri and Katharina Hansel and Paolo Amerio and Laura Atzori and Marco Galluzzo},
journal = {Acta Dermato-Venereologica},
year = {2026},
month = nov,
doi = {10.2340/actadv.v106.adv-2026-0815},
url = {https://doi.org/10.2340/actadv.v106.adv-2026-0815},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Explorative Correlation of Atopic Dermatitis Control Tool with Minimal Disease Activity Patient-reported Outcomes in Patients Treated with Upadacitinib: A Retrospective Real-world Study
AU - Filomena Russo
AU - Natale Schettini
AU - Giovanni Scaglione
AU - Ester Del Duca
AU - Tommaso Bianchelli
AU - Niccolò Gori
AU - Flavia Margiotta
AU - Laura Calabrese
AU - Elettra Antonelli
AU - Federica Giuliani
AU - Viviana Piras
AU - Sabatino Pallotta
AU - Chiara Bocchi
AU - Edoardo Mortato
AU - Camilla Chello
AU - Helena Gioacchini
AU - Maria Cannizzaro
AU - Marco Romanelli
AU - Laura Lazzeri
AU - Katharina Hansel
AU - Paolo Amerio
AU - Laura Atzori
AU - Marco Galluzzo
PY - 2026
DA - 2026/11/02
JO - Acta Dermato-Venereologica
DO - 10.2340/actadv.v106.adv-2026-0815
UR - https://doi.org/10.2340/actadv.v106.adv-2026-0815
AB - Atopic dermatitisis a chronic skin disease that requires long-term monitoring, which can be assessed using Atopic Dermatitis Control Tool (ADCT). Achieving minimal disease activity is also becoming an important issue in the treatment of atopic dermatitis. We aimed to identify which minimal disease sctivity patient-reported outcomes most closely reflect ADCT-defined disease control. We conducted a multicentric, observational retrospective study in patients with moderate-to-severe atopic dermatitis treated with upadacitinib. Outcome measures were collected at different time points (Week 0, 4, 16, 32, 52). Longitudinal changes were assessed with the paired Wilcoxon signedrank test; cross-sectional ADCT–patient-reported outcomes associations were evaluated at each visit using Spearman rank correlation coefficient (ρ). A total of 212 were included. All outcomes improved significantly from Week 4 onwards (all p<0.001). An ADCT score<7 was reached by 84.6% of evaluable patients at Week 4 and 90.1% at Week 52. At each timepoint, ADCT showed the strongest correlation with POEM (ρ range: 0.64–0.64) compared to other minimal disease sctivity patient-reported outcomes. These findings indicate that, among the minimal disease sctivity patient-reported outcomes, POEM most closely reflects the patient’s perception of atopic dermatitis control assessed by ADCT. Larger prospective studies are warranted to confirm these preliminary observations.
SN - 0001-5555
SN - 1651-2057
ER -